<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:4bf8cab8-8459-49b9-9b18-c5c69cc9d3b6"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="01911e2d-663a-44cf-bad6-d8cbecabd4be"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-11T00:26:06Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:9c41b25a-7bd9-4939-9872-c5b3259f62f5"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="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"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="Б. ЛИСТОВКА"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <b><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Листовка: информация за пациента</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid; background:white"><span lang="BG"> </span></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Kalydeco 75 mg филмирани таблетки</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Kalydeco 150 mg филмирани таблетки</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><span lang="BG">ивакафтор (</span><span lang="EN-GB">i</span><span lang="BG">vacaftor)</span></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Прочетете внимателно цялата листовка, преди да започнете да приемате това лекарство, тъй като тя съдържа важна за Вас информация.</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Запазете тази листовка. Може да се наложи да я прочетете отново.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Ако имате някакви допълнителни въпроси, попитайте Вашия лекар или фармацевт.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Това лекарство е предписано лично на Вас. Не го преотстъпвайте на други хора. То може да им навреди, независимо че признаците на тяхното заболяване са същите като Вашите.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Ако получите някакви нежелани реакции, уведомете Вашия лекар или фармацевт.<span style="color:red"> </span>Това включва и всички възможни<span style="color: red"> </span>нежелани реакции, неописани в тази листовка. Вижте точка 4.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="Какво съдържа тази листовка "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"> </p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG">1.       </span><span lang="BG">Какво представлява Kalydeco и за какво се използва</span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       Какво трябва да знаете, преди да приемете Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       Как да приемате Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       Възможни нежелани реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       Как да съхранявате Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       Съдържание на опаковката и допълнителна информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">1.       </span></b><b><span lang="BG">Какво представлява Kalydeco и за какво се използва</span></b></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Kalydeco съдържа активната съставка ивакафтор. Ивакафтор действа на нивото на регулатора на трансмембранната проводимост </span><span lang="BG">при кистозна фиброза (CFTR), белтък, който образува канал на клетъчната повърхност, позволяващ движението на частици, като например хлорни йони, навътре и навън от клетката. Поради мутации на гена <i>CFTR</i> (вижте по-долу), движението на хлорните йони е ограничено при хора с кистозна фиброза (КФ). Ивакафтор помага на някои от белтъците CFTR с отклонения да се отварят по-често, за да се подобри движението на хлорните йони навътре и навън от клетката.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Таблетките Kalydeco са предназначени:</span></p><p class="labeltext" style="margin-left:.5in;text-indent:-.25in"><span lang="BG">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style='font-family:"Times New Roman",serif'>Като монотерапия за пациенти </span><span lang="BG" style='font-family:"Times New Roman",serif'>на възраст 6 и повече години и с тегло 25</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'> или повече с кистозна фиброза (КФ), които имат </span><i><span style='font-family:"Times New Roman",serif'>R117H CFTR</span></i><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>мутация или една от следните водещи до каналопатии мутации на <i>CFTR</i> гена: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>или<i> S549R</i>.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoListParagraph" style="text-indent:-.25in;text-autospace:none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">В комбинация с таблетки тезакафтор/ивакафтор за пациенти на 6 и повече години с КФ, които имат две </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">мутации в<i> </i></span><i><span lang="EN-GB">CFTR</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">гена (хомозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="BG">),</span><span lang="BG"> или които имат мутация </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">и определени други втори мутации, които водят до намалено количество и/или функция на белтъка </span><span lang="FR">CFTR</span><span lang="BG"> (хетерозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del </span></i><span lang="BG">с мутация с<i> </i>остатъчна активност </span><span lang="EN-GB">(RF)</span><span lang="BG">). Ако Ви е предписано да приемате </span><span lang="EN-GB">Kalydeco</span><span lang="EN-GB"> </span><span lang="BG">с тезакафтор/ивакафтор, прочетете листовката, приложена към тях. Тя съдържа важна информация за това как да се приемат тези две лекарства. </span></p><p class="MsoListParagraph"><span lang="BG"> </span></p><p class="MsoListParagraph" style="text-indent:-.25in;text-autospace:none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">В комбинация с таблетки ивакафтор/тезакафтор/елексакафтор за пациенти на възраст 12 и повече години с КФ, които са хомозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">в<i> </i></span><i><span lang="EN-GB">CFTR</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">гена или хетерозиготни за мутацията </span><i><span lang="EN-GB">F</span></i><i><span lang="BG">508</span></i><i><span lang="EN-GB">del</span></i><span lang="EN-GB"> </span><span lang="BG">в<i> </i></span><i><span lang="EN-GB">CFTR</span></i><i><span lang="EN-GB"> </span></i><span lang="BG">гена с мутация с минимална функция (МФ). Мутацията с минимална функция се дефинира като водеща или до липса на синтез на белтък</span><i><span lang="BG"> </span></i><span lang="EN-GB">CFTR</span><span lang="BG">, или синтез на белтък </span><span lang="EN-GB">CFTR</span><span lang="BG">, който не функционира и който има малка вероятност да има отговор към ивакафтор самостоятелно и на тезакафтор/ивакафтор. Ако Ви е предписано да приемате </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> с ивакафтор/тезакафтор/елексакафтор, прочетете листовката, приложена</span><span lang="BG"> </span><span lang="BG">към тях. Тя съдържа важна информация за това как да се приемат тези две лекарства.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><b><span lang="BG"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="2.       Какво трябва да знаете, преди да приемете Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Не приемайте Kalydeco:</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ако сте алергични към ивакафтор или към някоя от останалите съставки на това лекарство (изброени в точка 6).</span></p><p class="MsoNormal"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Предупреждения и предпазни мерки "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете</span><span lang="BG"> с Вашия лекар, ако имате или преди това сте имали чернодробни проблеми. Може да се наложи Вашият лекар да коригира дозата.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt;page-break-after: avoid;text-autospace:none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">При някои хора, приемащи </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> (самостоятелно или в комбинация с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор)</span><span lang="BG">, се наблюдават повишени чернодробни ензими</span><span lang="BG"> в </span><span lang="BG">кръвта. Веднага кажете на Вашия лекар, ако имате някои от тези симптоми, които могат да са признаци на чернодробни проблеми:</span></p><p class="MsoNormal" style="margin-left:57.3pt;text-indent:-.5in;page-break-after: avoid;text-autospace:none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка или дискомфорт в горната дясна част на корема</span></p><p class="MsoNormal" style="margin-left:57.3pt;text-indent:-.5in;text-autospace: none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">пожълтяване на кожата или на бялото на очите</span></p><p class="MsoNormal" style="margin-left:57.3pt;text-indent:-.5in;text-autospace: none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">загуба на апетит</span></p><p class="MsoNormal" style="margin-left:57.3pt;text-indent:-.5in;text-autospace: none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">гадене или повръщане</span></p><p class="MsoNormal" style="margin-left:57.3pt;text-indent:-.5in;text-autospace: none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">тъмна урина. </span></p><p class="MsoNormal" style="margin-left:.25in"><span lang="BG">Преди и по време на лечението, особено през първата година и по-специално ако Вашите кръвни изследвания показват повишени чернодробни ензими в миналото, Вашият лекар ще направи някои кръвни изследвания, за да провери черния Ви дроб</span><span lang="RU">.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете с Вашия лекар, ако имате или преди сте имали бъбречни проблеми.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">Kalydeco</span><span lang="EN-GB"> </span><span lang="BG">(самостоятелно или в комбинация с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор) не се препоръчва, ако сте претърпели трансплантация на орган.</span></p><p class="MsoListParagraph"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете с Вашия лекар, ако използвате хормонален контрацептив – например, жени, които използват противозачатъчни таблетки. Това може да означава, че има по-голяма вероятност да получите обрив, докато приемате </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> в комбинация с ивакафтор/тезакафтор/елексакафтор.</span></p><p class="MsoListParagraph" style="margin-left:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">При някои деца и юноши, лекувани с </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> (самостоятелно или в комбинация с тезакафтор/ивакафтор или ивакафтор/тезакафтор/елексакафтор)</span><span lang="BG">, се наблюдава аномалия на очната леща (перде), без да се повлиява зрението. Вашият лекар може да извърши очни прегледи преди и по време на лечението.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;line-height: 13.0pt;text-autospace:none"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">Kalydeco</span><span lang="BG"> (самостоятелно или в комбинация с тезакафтор/ивакафтор или с ивакафтор/тезакафтор/елексакафтор) трябва да се прилага само ако имате една от мутациите на </span><i><span lang="EN-GB">CFTR</span></i><span lang="BG"> гена, указани в точка</span><span lang="EN-GB"> </span><span lang="BG">1 („</span><span lang="BG">Какво представлява Kalydeco и за какво се използва“).</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Деца и юноши"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не давайте това лекарство на деца под 4-месечна възраст, тъй като не е известно дали ивакафтор е безопасен и ефикасен при тези деца.</span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="MsoNormal"><span lang="BG">Не давайте това лекарство в комбинация с тезакафтор/ивакафтор на деца под 6-годишна възраст или в комбинация с ивакафтор/тезакафтор/елексакафтор на деца под 12‑годишна възраст, тъй като не е известно дали те са безопасни и ефикасни за тях.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Други лекарства и Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Трябва да кажете на Вашия лекар или фармацевт</span><span lang="BG">, ако използвате или наскоро сте използвали или е възможно да използвате други лекарства. Някои лекарства могат да повлияят начина, по който действа </span><span lang="EN-GB">Kalydeco</span><span lang="BG">, или да повишат вероятността </span><span lang="BG">да получите</span><span lang="BG"> нежелани реакции. По-специално, информирайте Вашия лекар, ако приемате някое от изброените по-долу лекарства. Вашият лекар може да реши да коригира дозата или да реши, че се нуждаете от допълнителни прегледи.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">противогъбични лекарства</span></b><span lang="BG"> (използвани за лечението на гъбични инфекции). Те включват флуконазол, итраконазол, кетоконазол, позаконазол и вориконазол.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">антибиотици</span></b><span lang="BG"> (използвани за лечението на бактериални инфекции). Те включват кларитромицин, еритромицин, рифабутин, рифампицин и телитромицин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства</span></b><span lang="BG"> <b>при епилепсия</b> (използвани за лечение на епилептични припадъци или гърчове). Те включват к</span><span lang="BG">арбамазепин, </span><span lang="BG">фенобарбитал </span><span lang="BG">и фенитоин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">билкови лекарства.</span></b><span lang="BG"> Те включват жълт кантарион (<i>Hypericum perforatum</i>).</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">имуносупресори</span></b><span lang="BG"> (използвани след органна трансплантация). Те включват циклоспорин, еверолимус, сиролимус и такролимус.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">сърдечни гликозиди</span></b><span lang="BG"> (използвани за лечение на някои сърдечни заболявания). Те включват дигоксин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">антикоагуланти</span></b><span lang="BG"> (използвани за предотвратяване на кръвни съсиреци). Те включват варфарин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства за диабет. </span></b><span lang="BG">Те включват глимепирид и глипизид.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства за понижаване на кръвното налягане. </span></b><span lang="BG">Те включват верапамил.<b> </b></span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Kalydeco с храна и напитки"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Избягвайте храни или напитки, съдържащи грейпфрут, по време на лечението с Kalydeco, тъй като те могат да увеличат нежеланите реакции на Kalydeco, като повишат количеството ивакафтор във Вашия организъм.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Бременност и кърмене"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Ако сте бременна или кърмите, смятате, че може да сте бременна или планирате бременност, посъветвайте</span><span lang="BG"> се с Вашия лекар преди употребата на това лекарство. Може би ще бъде по-добре да избягвате да използвате </span>Kalydeco<span lang="BG"> по време на бременност, ако е възможно, и Вашият лекар ще Ви помогне да решите какво е най-добре за Вас и Вашето дете.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не е известно дали </span><span lang="BG">ивакафтор</span><span lang="BG"> се екскретира в кърмата. Ако планирате да кърмите, попитайте Вашия лекар за съвет</span><span lang="EN-GB">,</span><span lang="BG"> преди да приемате Kalydeco. Вашият лекар ще реши дали да препоръча да спрете да кърмите или да спрете терапията с ивакафтор. Вашият лекар ще вземе предвид ползата от кърменето за детето и ползата от терапията за Вас. </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Шофиране и работа с машини"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco може да Ви накара да се почувствате замаяни. Ако се почувствате замаяни, не шофирайте, не карайте велосипед и не работете с машини.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><b><span lang="BG">Важна информация за съдържанието на Kalydeco</span></b></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Kalydeco съдържа лактоза. Ако Вашият лекар Ви е казал, че имате непоносимост към някои захари, свържете се с него, преди да приемете това лекарство."/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Kalydeco съдържа лактоза. Ако Вашият лекар Ви е казал, че имате непоносимост към някои захари, свържете се с него, преди да приемете това лекарство."/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       Как да приемате Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Винаги приемайте това лекарство точно както Ви е казал Вашият лекар. Ако не сте сигурни в нещо, попитайте Вашия лекар. </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Вашият лекар ще определи кое лекарство и доза са подходящи за Вас.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Препоръки за дозиране на </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> са дадени в Таблица 1.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="labeltext" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Таблица 1. Препоръки за дозиране</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="width:469.6pt;margin-left:-.25pt;border-collapse:collapse;border:none" width="626"> <thead> <tr style="page-break-inside:avoid;height:16.25pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><b><span style='font-family:    "Times New Roman",serif'> </span></b></p> </td> <td style="width:234.2pt;border:solid windowtext 1.0pt;border-left:    none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="312"> <p align="center" class="labeltext" style="text-align:center;page-break-after:    avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Сутрин</span></b></p> </td> <td style="width:129.05pt;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="172"> <p align="center" class="labeltext" style="text-align:center;page-break-after:    avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Вечер</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid;height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco </span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>като   монотерапия</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:16.25pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>6 и   повече   години, </span><span style='font-family:   "Times New Roman",serif'>≥25</span><span lang="BG" style='font-family:   "Times New Roman",serif'> </span><span lang="FR" style='font-family:"Times New Roman",serif'>kg</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка </span><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco<b> </b></span><span lang="BG" style='font-family:"Times New Roman",serif'>150 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:16.25pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка </span><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="BG" style='font-family:"Times New Roman",serif'> 150 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco </span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>в   комбинация   с   тезакафтор/ивакафтор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>От   6 до под 12 години,   &lt;</span><span style='font-family:"Times New Roman",serif'>30</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="FR" style='font-family:"Times New Roman",serif'>kg</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   тезакафтор   50 mg/   ивакафтор 75 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка </span><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="BG" style='font-family:"Times New Roman",serif'> 75 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>От   6 до под 12 години,   </span><span style='font-family:"Times New Roman",serif'>≥30</span><span lang="BG" style='font-family:"Times New Roman",serif'> </span><span lang="FR" style='font-family:"Times New Roman",serif'>kg</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка   тезакафтор   100 mg/   ивакафтор 150 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка </span><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="BG" style='font-family:"Times New Roman",serif'> 150 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>12 и   повече   години</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка тезакафтор 100 mg/ивакафтор 150 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext" style="page-break-after:avoid"><span lang="BG" style='font-family:"Times New Roman",serif'>Една   таблетка </span><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="BG" style='font-family:"Times New Roman",serif'> 150 mg</span></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td colspan="3" style="width:469.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="626"> <p class="labeltext" style="page-break-after:avoid"><b><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco </span></b><b><span lang="BG" style='font-family:"Times New Roman",serif'>в   комбинация   с ивакафтор/тезакафтор/елексакафтор</span></b></p> </td> </tr> <tr style="page-break-inside:avoid;height:15.3pt"> <td style="width:106.35pt;border:solid windowtext 1.0pt;border-top:   none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="142"> <p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>12 и   повече   години</span></p> </td> <td style="width:234.2pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="312"> <p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Две   таблетки   ивакафтор 75 mg/   тезакафтор 50 mg/елексакафтор 100 mg</span></p> </td> <td style="width:129.05pt;border-top:none;border-left:none;   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.3pt" width="172"> <p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Една</span><span lang="BG" style='font-family:"Times New Roman",serif'> таблетка   </span><span lang="BG" style='font-family:"Times New Roman",serif'>Kalydeco</span><span lang="BG" style='font-family:"Times New Roman",serif'> 150 mg</span></p> </td> </tr> </table><p class="labeltext"><span style='font-family:"Times New Roman",serif'> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Приемайте дозите сутрин и вечер приблизително </span>през <span lang="BG">12 часа с храна, съдържаща мазнини. </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Трябва да продължите да използвате всички други лекарства, които използвате, освен ако Вашият лекар не Ви каже да спрете някои от тях.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Ако имате чернодробни проблеми, умерени или тежки, може да се наложи Вашият лекар да намали дозата </span><span lang="BG">на Вашите таблетки, тъй като Вашият черен дроб няма да очиства лекарството толкова бързо, колкото при хора с нормална чернодробна функция.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Употреба при деца"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Това лекарство е за перорално приложение. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Поглъщайте таблетката цяла. Не разчупвайте, не дъвчете и не разтваряйте таблетките. Приемайте таблетките </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> с храна, която съдържа мазнини.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Основни хранения или закуски, които съдържат мазнини, са ястията, приготвени с масло или различни видове олио, или съдържащите яйца. Други храни, съдържащи мазнини, са</span><span lang="EN-GB">:</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-.25in"><span lang="RU" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">сирене и кашкавал</span><span lang="RU">, </span><span lang="BG">пълномаслено мляко</span><span lang="RU">, </span><span lang="BG">млечни продукти от пълномаслено мляко</span><span lang="RU">, </span><span lang="BG">кисело мляко</span><span lang="RU">, </span><span lang="BG">шоколад</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-.25in"><span style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">месо</span>, <span lang="BG">мазна риба</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-.25in"><span lang="RU" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">авокадо</span><span lang="RU">, </span><span lang="BG">хумус</span><span lang="RU">, </span><span lang="BG">продукти на соева основа </span><span lang="RU">(</span><span lang="BG">тофу</span><span lang="RU">)</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ядки, съдържащи мазнини хранителни блокчета или напитки.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Ако сте приели повече от необходимата доза Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Можете да получите нежелани реакции, включително упоменатите в точка</span><span lang="EN-GB"> </span><span lang="BG">4 по-долу. Ако това е така, потърсете Вашия лекар или фармацевт за съвет. Ако е възможно, носете Вашето лекарство и тази листовка със себе си.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><i><span lang="BG"> </span></i></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Ако сте пропуснали да приемете Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Вземете пропуснатата доза, ако са изминали по-малко от 6 часа от момента, в който сте я пропуснали. В противен случай, изчакайте до следващата доза по схемата, както нормално бихте направили. Не вземайте двойна доза, за да компенсирате пропуснатата доза.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Ако сте спрели приема на Kalydeco "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Приемайте </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> толкова дълго, колкото Ви е препоръчал Вашият лекар. Не спирайте, освен ако Вашият лекар не Ви посъветва за това. Ако имате някакви допълнителни въпроси, свързани с употребата на това лекарство, попитайте Вашия лекар или фармацевт.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       Възможни нежелани реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Както всички лекарства, това лекарство може да предизвика нежелани реакции, въпреки че не всеки ги получава. </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Сериозни</span></b><b><span lang="BG"> нежелани реакции</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Болка в стомаха (корема) и повишени чернодробни ензими в кръвта. </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Възможни признаци на чернодробни проблеми</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Повишението на чернодробните ензими в кръвта е често срещано при пациенти с КФ. Това може да е признак на чернодробни проблеми:</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка или дискомфорт в горната дясна област на стомаха (корема)</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">пожълтяване на кожата или бялата част на очите</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">загуба на апетит</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">гадене или повръщане</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">тъмна урина.</span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Говорете незабавно с Вашия лекар</span></b><span lang="BG">, ако получите някои от тези нежелани реакции.</span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Много чести</span></b><span lang="BG"> нежелани реакции (могат да засегнат повече от 1 на 10 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">инфекция на горните дихателни пътища (настинка), включително възпалено гърло и запушен нос</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">главоболие </span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">замаяност</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">диария</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка в стомаха или корема</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">промени във вида на бактериите в храчките</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">повишени чернодробни ензими (признаци на натоварване на черния дроб)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">обрив.</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Чести</span></b><span lang="BG"> нежелани реакции (могат да засегнат до 1 на 10 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">хрема</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка в ухото, ушен дискомфорт</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">звънене в ушите</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">зачервяване на вътрешността на ухото</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарушение на вътрешното ухо (замайване или световъртеж)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">проблеми със синусите (запушване на синусите)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">зачервяване на гърлото</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">бучка в гърдата</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">гадене</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">грип</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ниска кръвна захар (хипогликемия)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарушено дишане (задъхване или затруднено дишане)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">газове (флатуленция)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">пъпки (акне)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">сърбеж по кожата</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">повишена креатин фосфокиназа (признак на разграждане на мускулите), наблюдавана при кръвните изследвания.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Нечести</span></b><b><span lang="BG"> </span></b><span lang="BG">нежелани реакции</span><span lang="BG"> (могат да засегнат до 1 на 100 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">запушване на ухото</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">възпаление на гърдата</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарастване на гърдата при мъже</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">изменения или болка в гръдното зърно</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">хриптене</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">повишено кръвно налягане.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Допълнителни нежелани реакции при деца и юноши"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Нежеланите реакции при деца и юноши са подобни на тези, наблюдавани при възрастните. Повишени чернодробни ензими в кръвта обаче се наблюдават по-често при малки деца.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Съобщаване на нежелани реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Ако получите някакви нежелани лекарствени реакции, уведомете Вашия лекар или фармацевт. Това включва всички възможни,<span style="color:red"> </span>неописани в тази листовка нежелани реакции. Можете също да съобщите нежелани реакции директно чрез <span style="background:lightgrey">националната система за съобщаване, посочена в </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span lang="BG" style="background:lightgrey">Приложение V</span></a></span><span lang="BG">. Като съобщавате нежелани реакции, можете да дадете своя принос за получаване на повече информация относно безопасността на това лекарство.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       Как да съхранявате Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Да се </span><span lang="BG">съхранява на място, недостъпно за деца.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не използвайте това лекарство след срока на годност, отбелязан върху опаковката след „Годен до:“ и „</span><span lang="EN-GB">EXP</span><span lang="BG">“.</span><span lang="BG"> Срокът на годност отговаря на последния ден от посочения месец.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Това лекарство не изисква специални условия на съхранение.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не изхвърляйте лекарствата</span><span lang="BG"> в канализацията или в контейнера за домашни отпадъци. Попитайте Вашия фармацевт как да изхвърляте лекарствата, които вече не използвате. Тези мерки ще спомогнат за опазване на околната среда.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       Съдържание на опаковката и допълнителна информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Какво съдържа Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG">Активно вещество: ивакафтор. </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG">Kalydeco 75 mg филмирани таблетки</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG">Всяка филмирана таблетка от </span><span lang="BG">75 mg съдържа 75 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG">Kalydeco 150 mg филмирани таблетки</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG">Всяка филмирана таблетка от </span><span lang="BG">150 mg съдържа 150 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Други съставки:</span></p><p class="MsoNormal" style="margin-left:31.45pt;text-indent:-13.6pt"><span lang="BG" style="font-size:10.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Ядро на таблетката: микрокристална целулоза, лактоза монохидрат, хипромелозен ацетат сукцинат, кроскармелоза натрий, натриев </span><span lang="BG">лаурилсулфат</span><span lang="EN-GB"> (E487)</span><span lang="BG">, силициев диоксид, колоиден безводен, и магнезиев стеарат. </span></p><p class="MsoNormal" style="margin-left:31.45pt;text-indent:-13.6pt"><span lang="BG" style="font-size:10.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Покритие:<i> </i>поливинилов алкохол, титанов диоксид</span><span lang="EN-GB"> (E171)</span><span lang="BG">, макрогол </span><span lang="BG">(</span><span lang="EN-GB">PEG </span><span lang="BG">3350)</span><span lang="BG">, талк, индигокармин алуминиев лак</span><span lang="EN-GB"> (E132)</span><span lang="EN-GB"> </span><span lang="BG">и карнаубски восък. </span></p><p class="MsoNormal" style="margin-left:31.45pt;text-indent:-13.6pt"><span lang="BG" style="font-size:10.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Печатно мастило: </span><span lang="BG">шеллак, черен железен диоксид </span><span lang="EN-GB">(E172)</span><span lang="BG">, пропиленгликол</span><span lang="EN-GB"> (E1520)</span><span lang="EN-GB"> </span><span lang="BG">и р</span><span lang="BG">азтвор на </span><span lang="BG">амоняк, концентриран</span><span lang="BG">.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Вижте края на точка</span><span lang="EN-GB"> </span><span lang="BG">2 - „</span><span lang="BG">Важна информация за съдържанието на Kalydeco“.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.65pt;margin-bottom:.0001pt;text-indent:-13.65pt"><b><span lang="BG"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Как изглежда Kalydeco и какво съдържа опаковката"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Kalydeco 75 mg </span><span lang="BG">филмирани таблетки са светлосини таблетки с формата на капсула с размер </span><span lang="EN-GB">12</span><span lang="BG">,</span><span lang="EN-GB">7 mm x 6</span><span lang="BG">,</span><span lang="EN-GB">8 mm, </span><span lang="BG">с отпечатано „V</span><span lang="EN-GB"> </span><span lang="BG">75” с черно мастило от едната страна и без надпис от другата</span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Предлагат се следните опаковки</span><span lang="EN-GB">: </span></p><p class="MsoListParagraph" style="margin-top:0in;margin-right:-.1pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка с блистер-карти, съдържаща </span><span lang="EN-GB">28 </span><span lang="BG">филмирани таблетки</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal"><span lang="BG">Kalydeco 150 mg филмирани таблетки са светлосини таблетки с формата на капсула с размер 16,5 mm x 8,4 mm, с отпечатано „V</span><span lang="EN-GB"> </span><span lang="BG">150” с черно мастило от едната страна и без надпис от другата.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Предлагат се следните опаковки:</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка с блистер-карти, съдържаща 28 филмирани таблетки</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка с блистери, съдържаща 56</span><span lang="EN-GB"> </span><span lang="BG">филмирани таблетки</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Бутилка, съдържаща 56</span><span lang="EN-GB"> </span><span lang="BG">филмирани таблетки</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Притежател на разрешението за употреба</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Vertex Pharmaceuticals (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="EN-GB">Ирландия</span><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Тел.: </span><span lang="EN-GB">+353 (0)1 761 7299</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Производител</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Almac Pharma Services (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Finnabair Industrial Estate</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dundalk</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Co. Louth</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">A91 P9KD</span></p><p class="MsoNormal"><span lang="EN-GB">Ирландия</span><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Almac</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Pharma</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Services</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Seagoe</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Industrial</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Estate</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Craigavon</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">County</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Armagh</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">BT</span><span lang="BG" style="color:black;background:lightgrey">63 5</span><span lang="EN-GB" style="color:black;background:lightgrey">UA</span></p><p class="MsoNormal"><span lang="BG" style="color:black;background:lightgrey">Обединено кралство</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Дата на последно преразглеждане на листовката "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><i><span lang="BG"> </span></i></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Други източници на информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Подробна информация за това лекарствo е предоставена на уебсайта на Европейската агенция по лекарствата</span><span lang="BG"> </span><span lang="EN-GB"><a href="http://www.emea.europa.eu"><span lang="BG">http://www.ema.europa.eu</span></a></span><span lang="BG" style="color:blue">.</span><span lang="BG"> Посочени </span><span lang="BG">са също линкове към други уебсайтове, където може да се намери информация за редки заболявания и лечения.</span></p><span lang="BG" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Листовка: информация за пациента</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid; background:white"><span lang="BG"> </span></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Kalydeco 25 mg гранули в саше</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Kalydeco 50 mg гранули в саше</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><b><span lang="BG">Kalydeco 75 mg гранули в саше</span></b></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><span lang="BG">ивакафтор (</span><span lang="EN-GB">i</span><span lang="BG">vacaftor)</span></p><p align="center" class="MsoNormal" style="text-align:center;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Прочетете внимателно цялата листовка, преди Вашето дете да започне да приема това лекарство, тъй като тя съдържа важна за Вашето дете информация.</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Запазете тази листовка. Може да се наложи да я прочетете отново.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Ако имате някакви допълнителни въпроси, попитайте лекаря на Вашето дете или фармацевта.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Това лекарство е предписано лично на Вашето дете. Не го преотстъпвайте на други хора. То може да им навреди, независимо че признаците на тяхното заболяване са същите като на Вашето дете.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Ако Вашето дете получи някакви нежелани реакции, уведомете лекаря на Вашето дете или фармацевта. Това включва и всички възможни<span style="color:red"> </span>нежелани реакции, неописани в тази листовка. Вижте точка 4.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="Какво съдържа тази листовка "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"> </p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG">1.       </span><span lang="BG">Какво представлява Kalydeco и за какво се използва</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG">2.       Какво трябва да знаете, преди</span><span lang="BG"> Вашето дете да приеме Kalydeco</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-1.4pt;margin-bottom: 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="BG">3.       </span><span lang="BG">Как се приема Kalydeco</span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       Възможни нежелани реакции"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       Как да съхранявате Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       Съдържание на опаковката и допълнителна информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">1.       </span></b><b><span lang="BG">Какво представлява Kalydeco и за какво се използва</span></b></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Kalydeco съдържа активната съставка ивакафтор. Ивакафтор действа на нивото на регулатора на трансмембранната проводимост </span><span lang="BG">при кистозна фиброза (CFTR), белтък, който образува канал на клетъчната повърхност, позволяващ движението на частици, като например хлорни йони, навътре и навън от клетката. Поради мутации на гена <i>CFTR</i> (вижте по-долу), движението на хлорните йони е ограничено при хора с кистозна фиброза (КФ). Ивакафтор помага на някои от белтъците CFTR с отклонения да се отварят по-често, за да се подобри движението на хлорните йони навътре и навън от клетката.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Гранулите Kalydeco са предназначени за лечение на бебета и </span><span lang="BG" style='font-family:"Times New Roman",serif'>деца на възраст 4 и повече месеца и с тегло от 5</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'> до под 25</span><span style='font-family:"Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> <span lang="BG">с кистозна фиброза (КФ), които имат </span></span><i><span style='font-family:"Times New Roman",serif'>R117H CFTR</span></i><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>мутация или една от следните водещи до каналопатии мутации на <i>CFTR</i> гена: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>или<i> S549R</i>.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">2.       </span></b><b><span lang="BG">Какво трябва да знаете, преди Вашето дете да приеме Kalydeco</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Да не се приема Kalydeco</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ако Вашето дете е алергично към ивакафтор или към някоя от останалите съставки на това лекарство (изброени в точка 6).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Предупреждения и предпазни мерки </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете с лекаря на Вашето дете, ако детето Ви има или преди това е имало чернодробни проблеми</span><span lang="BG">. </span><span lang="BG">Може да се </span><span lang="BG">наложи</span><span lang="BG"> лекарят на Вашето дете да коригира дозата му.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">При някои хора, приемащи </span><span lang="BG">Kalydeco</span><span lang="BG">, се наблюдават повишени чернодробни ензими в кръвта. Веднага кажете на лекаря на Вашето дете, ако то има някои от тези симптоми, които могат да са признаци на чернодробни проблеми:</span></p><ul style="margin-top:0in" type="disc"> <li class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">болка или      дискомфорт      в горната      дясна част      на корема</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">пожълтяване      на кожата      или на      бялото на      очите</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">загуба      на апетит</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">гадене      или      повръщане</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">тъмна      урина.</span></li> </ul><li class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">болка или      дискомфорт      в горната      дясна част      на корема</span></li><span lang="BG">болка или      дискомфорт      в горната      дясна част      на корема</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">пожълтяване      на кожата      или на      бялото на      очите</span></li><span lang="BG">пожълтяване      на кожата      или на      бялото на      очите</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">загуба      на апетит</span></li><span lang="BG">загуба      на апетит</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">гадене      или      повръщане</span></li><span lang="BG">гадене      или      повръщане</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">тъмна      урина.</span></li><span lang="BG">тъмна      урина.</span><p class="MsoNormal" style="margin-left:21.3pt"><span lang="BG">Преди и по време на лечението на Вашето дете, особено през първата година и по-специално ако кръвните изследвания показват чернодробни ензими в миналото, лекарят на Вашето дете ще направи някои кръвни изследвания, за да провери черния му дроб</span><span lang="RU">.</span></p><p class="MsoNormal" style="margin-left:21.3pt"><span lang="RU"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете с лекаря на Вашето дете, ако Ви е известно, че то има или преди това е имало бъбречни проблеми. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">Kalydeco</span><span lang="BG"> не се препоръчва за пациенти, които са претърпели трансплантация на орган.</span></p><p class="MsoListParagraph" style="margin-left:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">При някои деца и юноши по време на лечението се наблюдава аномалия на очната леща (перде), без да се повлиява зрението. </span></p><p class="MsoNormal" style="margin-left:21.3pt"><span lang="BG">Лекарят на Вашето дете може да проведе очни прегледи преди и по време на лечението с </span><span lang="BG">ивакафтор</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Деца </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не давайте това лекарство на </span><span lang="BG">деца под 4‑месечна възраст, тъй като не е известно дали </span><span lang="BG">ивакафтор </span><span lang="BG">е безопасен и ефикасен при тези деца</span><span lang="BG">.</span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Други лекарства и Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Трябва да кажете на лекаря на Вашето дете или фармацевта</span><span lang="BG">, ако то използва, наскоро е използвало или е възможно да използва други лекарства. Някои лекарства могат да повлияят начина, по който действа </span><span lang="EN-GB">Kalydeco</span><span lang="BG">, или да повишат вероятността </span><span lang="BG">да получите</span><span lang="BG"> нежелани реакции. По-специално, информирайте лекаря на Вашето дете, ако то приема някое от изброените по-долу лекарства. Лекарят на Вашето дете може да реши да коригира дозата му или да реши, че са нужни допълнителни прегледи.</span><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">противогъбични лекарства</span></b><span lang="BG"> (използвани за лечението на гъбични инфекции). Те включват </span><span lang="BG">флуконазол, итраконазол,</span><span lang="BG"> </span><span lang="BG">кетоконазол, позаконазол и вориконазол.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">антибиотици </span></b><span lang="BG">(използвани за лечението на бактериални инфекции). Те включват </span><span lang="BG">кларитромицин, еритромицин, рифабутин, рифампицин и телитромицин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства</span></b><span lang="BG"> <b>при епилепсия</b> (използвани за лечение на епилептични припадъци</span><span lang="BG"> </span><span lang="BG">или гърчове). Те включват</span><span lang="BG"> карбамазепин,</span><span lang="BG"> </span><span lang="BG">фенобарбитал и фенитоин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">билкови </span></b><b><span lang="BG">лекарства.</span></b><span lang="BG"> Те включват жълт кантарион (<i>Hypericum perforatum</i>).</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">имуносупресори</span></b><span lang="BG"> (използвани след органна трансплантация). Те включват </span><span lang="BG">циклоспорин, </span><span lang="BG">еверолимус, сиролимус и </span><span lang="BG">такролимус</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">сърдечни гликозиди</span></b><span lang="BG"> (използвани за лечение на някои сърдечни заболявания). Те включват дигоксин</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">антикоагуланти</span></b><span lang="BG">(използвани за предотвратяване на кръвни съсиреци). Те включват варфарин. </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства за диабет.</span></b><span lang="BG"> Те включват глимепирид и глипизид.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства за понижаване на кръвното налягане. </span></b><span lang="BG">Те включват верапамил.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Kalydeco с храна и напитки</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Избягвайте да давате на Вашето дете храни или напитки, съдържащи грейпфрут, по време на лечението с Kalydeco, тъй като те могат да увеличат нежеланите реакции на Kalydeco, като повишат количеството ивакафтор в организма му.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Шофиране и работа с машини</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco може да причини замаяност на Вашето дете. Ако детето Ви почувства замаяност, се препоръчва да не кара колело или да прави каквото и да е, което изисква цялото му внимание.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><b><span lang="BG">Важна информация за съдържанието на Kalydeco</span></b></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormalIndent" style="margin:0in"><b><span lang="BG">Kalydeco съдържа лактоза. </span></b><span lang="BG">Ако лекарят на Вашето дете Ви е казал, че то има непоносимост към някои захари, свържете се с него, преди детето Ви да вземе това лекарство.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in"><b><span lang="BG">Kalydeco </span></b><b><span lang="BG">съдържа по-малко от 1</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">mmol</span></b><span lang="BG"> <b>натрий</b> (23</span><span lang="EN-GB"> </span><span lang="BG">mg) на доза, т.е. може да се каже, че практически не съдържа натрий.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">3.       </span></b><b><span lang="BG">Как се приема Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Винаги давайте това лекарство на Вашето дете точно както Ви е казал неговият лекар. Ако не сте сигурни в нещо, попитайте лекаря на Вашето дете. </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Лекарят на Вашето дете ще определи правилната доза за детето. Вашето дете трябва да продължи да приема всички други лекарства, освен ако лекарят на Вашето дете не му каже да спре някои от тях.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Препоръки за дозиране на Kalydeco са дадени в Таблица 1.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><i><span lang="BG"> </span></i></b></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG">Таблица 1: Препоръки за дозиране за деца на възраст 4 месеца</span></b><b><span lang="BG"> </span></b><b><span lang="BG">и по-големи</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.0%;border-collapse:collapse;border:none" width="99%"> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Възраст</span></b></p> </td> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Тегло</span></b></p> </td> <td style="width:36.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Доза</span></b></p> </td> <td style="width:20.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Обща   дневна доза</span></b></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   4 месеца до   под 6 месеца</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">5</span><span lang="EN-GB"> kg</span><span lang="BG"> или   повече</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от </span><span lang="EN-GB">25</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули,   приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">50</span><span lang="BG"> </span><span lang="EN-GB">mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td rowspan="4" style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">6</span><span lang="BG"> и повече   месеца</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   5</span><span lang="EN-GB"> kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под 7</span><span lang="EN-GB"> kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от </span><span lang="EN-GB">25</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули   Kalydeco, приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини </span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">50 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">7 kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под </span><span lang="EN-GB">14 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от </span><span lang="EN-GB">50</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули   Kalydeco, приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини </span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">100 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">14 kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под </span><span lang="EN-GB">25 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от 7</span><span lang="EN-GB">5</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули   Kalydeco, приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">150 mg</span></p> </td> </tr> <tr style="height:15.7pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="21%"> <p class="MsoNormal"><span lang="BG">2</span><span lang="EN-GB">5 kg</span><span lang="BG"> и повече</span></p> </td> <td colspan="2" style="width:56.64%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="BG">Вижте листовката   на Kalydeco таблетки</span></p> </td> </tr> </table><p class="MsoNormal" style="text-autospace:none"><span class="s10"><span lang="BG"> </span></span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG">Ако Вашето дете има чернодробни проблеми</span></b><span lang="BG">, може да се наложи лекарят на Вашето дете да намали дозата Kalydeco, тъй като черният дроб на детето Ви няма да изчиства лекарството толкова бързо, колкото при децата с нормална чернодробна функция. </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">Умерени чернодробни проблеми при деца на възраст 6 и повече месеца:</span></b><span lang="BG"> дозата може да се понижи до половината от указаната в горната таблица доза, тоест едно саше веднъж дневно.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">Тежки чернодробни проблеми при деца на възраст 6 и повече месеца:</span></b><span lang="BG"> препоръчва се да не се използва, но лекарят на Вашето дете ще реши дали е подходящо за детето да употребява това лекарство, в който случай дозата (както е указана в горната таблица) трябва да се понижи до едно саше през ден.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">Чернодробни проблеми при деца на възраст между 4 и 6 месеца:</span></b><span lang="BG"> препоръчва се да не се използва, но лекарят на Вашето дете ще реши дали е подходящо за детето да употребява това лекарство и в каква доза.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Kalydeco е за перорално приложение.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяко саше е само за еднократна употреба.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Как да давате Kalydeco на Вашето дете:</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol;color:black">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style="color:black">Хванете сашето с гранули, така че пунктираната линия за отрязване да е отгоре.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol;color:black">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style="color:black">Леко разклатете сашето, за да се събере съдържанието му.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol;color:black">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style="color:black">Откъснете или отрежете сашето по пунктираната линия. </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Смесете цялото съдържание на едно саше с </span><span lang="BG" style="color:black">5 ml</span><span lang="BG"> подходяща за възрастта мека храна или течност. Храната или течността трябва да са със стайна или по-ниска температура. Някои примери за подходящи за възрастта меки храни или течности са плодово или зеленчуково пюре, кисело мляко, ябълково пюре, вода, мляко, </span><span lang="RU">кърма, мляко на прах за кърмачета </span><span lang="BG">или сок.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">След като смесите продукта, дайте го веднага на Вашето дете. Ако това не е възможно, дайте го в рамките на следващия един час след смесването. Внимавайте цялата смес да бъде приета веднага.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Непосредствено преди или непосредствено след приложението трябва да се приеме основно хранене или закуска, богати на мазнини (някои примери са дадени по-долу). </span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Основни хранения и закуски, които съдържат мазнини, са ястията, приготвени с масло или различни видове олио, или съдържащите яйца. Други храни, съдържащи мазнини, са:</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">сирене и кашкавал, пълномаслено мляко, млечни продукти от пълномаслено мляко, кисело мляко, </span><span lang="RU">кърма, мляко на прах за кърмачета</span><span lang="EN-GB">,</span><span lang="EN-GB"> </span><span lang="BG">шоколад</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">месо</span>, <span lang="BG">мазна риба</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="RU" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">авокадо</span><span lang="RU">, </span><span lang="BG">хумус</span><span lang="RU">, </span><span lang="BG">продукти на соева основа </span><span lang="RU">(</span><span lang="BG">тофу</span><span lang="RU">)</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="RU" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ядки</span><span lang="RU">, </span><span lang="BG">съдържащи мазнини, хранителни блокчета или напитки.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Ако Вашето дете е приело повече от необходимата доза Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Вашето дете може да получи нежелани реакции, включително упоменатите в точка</span><span lang="EN-GB"> </span><span lang="BG">4 по-долу. Ако това е така, потърсете лекаря на Вашето дете или фармацевта за съвет. Ако е възможно, носете лекарството на Вашето дете и тази листовка със себе си.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Ако Вашето дете е пропуснало да приеме Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Дайте пропуснатата доза, ако са изминали по-малко от 6 часа от момента, в който Вашето дете я е пропуснало. В противен случай изчакайте до следващата доза на Вашето дете по схемата, както нормално бихте направили. Не давайте на Вашето дете двойна доза, за да компенсирате пропусната доза.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Ако сте спрели да давате Kalydeco на Вашето дете</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Давайте </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> на Вашето дете толкова дълго, колкото е препоръчал неговият лекар. Не спирайте, освен ако лекарят на Вашето дете не Ви посъветва за това. Ако имате някакви допълнителни въпроси, свързани с употребата на това лекарство, попитайте лекаря на Вашето дете или фармацевта.</span></p><p class="MsoNormal" style="margin-right:-.1pt"> </p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">4.       </span></b><b><span lang="BG">Възможни нежелани реакции</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Както всички лекарства, това лекарство може да предизвика нежелани реакции, въпреки че не всеки ги получава. </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Сериозни нежелани реакции</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Болка в стомаха (корема) и повишени чернодробни ензими в кръвта. </span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Възможни признаци на чернодробни проблеми</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Повишението на чернодробните ензими в кръвта е често срещано при пациенти с КФ. Това може да е признак на чернодробни проблеми:</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка или дискомфорт в горната дясна област на стомаха (корема)</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">пожълтяване на кожата или бялата част на очите</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">загуба на апетит</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">гадене или повръщане</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">тъмна урина.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Говорете незабавно с лекаря на Вашето дете, ако получите някои от тези нежелани реакции.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Много чести</span></b><span lang="BG"> нежелани реакции (могат да засегнат повече от 1 на 10 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">инфекция на горните дихателни пътища (настинка), включително възпалено гърло и запушен нос</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">главоболие </span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">замаяност</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">диария</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">обрив</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">промени във вида на бактериите в храчките.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Чести</span></b><span lang="BG"> нежелани реакции (могат да засегнат до 1 на 10 души)</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">хрема</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка в ухото, ушен дискомфорт</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">звънене в ушите</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">зачервяване на вътрешността на ухото </span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарушение на вътрешното ухо (замайване или световъртеж)</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">запушване на синусите</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">зачервяване на гърлото</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">бучка в гърдата.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Нечести</span></b><span lang="BG"> </span><span lang="BG">нежелани реакции (могат да засегнат до 1 на 100 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">запушване на ухото</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">възпаление на гърдата</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарастване на гърдата при мъже</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">изменения или болка в гръдното зърно.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:avoid"><b><span lang="BG">Допълнителни нежелани реакции при деца и юноши</span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:avoid"><span lang="RU"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;margin-bottom:.0001pt;text-indent:0in"><span lang="BG">Нежеланите реакции при деца <span style="display:none">и юноши</span> са подобни на тези, наблюдавани при възрастните. Повишени чернодробни ензими в кръвта обаче се наблюдават по-често при малки деца</span><span lang="RU">.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="RU"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Съобщаване на нежелани реакции</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Ако Вашето дете получи някакви нежелани лекарствени реакции, уведомете лекаря или фармацевта на Вашето дете. Това включва всички възможни,<span style="color:red"> </span>неописани в тази листовка нежелани реакции. Можете също да съобщите нежелани реакции директно чрез <span style="background:lightgrey">националната система за съобщаване, посочена в </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span lang="BG" style="background:lightgrey">Приложение V</span></a></span><span lang="BG">. Като съобщавате нежелани реакции, можете да дадете своя принос за получаване на повече информация относно безопасността на това лекарство.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">5.       </span></b><b><span lang="BG">Как да съхранявате</span></b><b><span lang="BG"> Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Да се </span><span lang="BG">съхранява на място, недостъпно за деца.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не използвайте това лекарство след срока на годност, отбелязан върху опаковката след „Годен до:“ и „</span><span lang="EN-GB">EXP</span><span lang="BG">“.</span><span lang="BG"> Срокът на годност отговаря на последния ден от посочения месец.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Това лекарство не изисква специални условия на съхранение.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Доказано е, че след като се смеси, сместа е стабилна в продължение на един час.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не изхвърляйте лекарствата</span><span lang="BG"> в канализацията или в контейнера за домашни отпадъци. Попитайте Вашия фармацевт как да изхвърляте лекарствата, които вече не използвате. Тези мерки ще спомогнат за опазване на околната среда.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Какво съдържа Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG">Kalydeco 25 mg гранули в саше:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><span lang="BG">Активно вещество: ивакафтор. Всяко саше съдържа 25 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG">Kalydeco 50 mg гранули в саше:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG">Активно вещество: ивакафтор. Всяко саше съдържа 50 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG">Kalydeco 75 mg гранули в саше:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG">Активно вещество: ивакафтор. Всяко саше съдържа 75 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:.25in;margin-bottom:.0001pt"><span lang="BG">Други съставки: </span><span lang="BG">силициев диоксид, колоиден безводен, кроскармелоза натрий, хипромелозен ацетат сукцинат, лактоза монохидрат, магнезиев стеарат, м</span><span lang="BG">анитол, захароза и натриев лаурилсулфат</span><span lang="BG"> </span><span lang="EN-GB">(E487).</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Вижте края на точка</span><span lang="EN-GB"> </span><span lang="BG">2 - „</span><span lang="BG">Важна информация</span><span lang="BG"> за съдържанието на Kalydeco“.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Как изглежда Kalydeco и какво съдържа опаковката"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal"><span lang="BG">Kalydeco 25</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">гранули в саше са бели до почти бели гранули.</span></p><p class="MsoNormal"><span lang="BG">Kalydeco 50</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">гранули в саше са бели до почти бели гранули.</span></p><p class="MsoNormal"><span lang="BG">Kalydeco 75</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">гранули в саше са бели до почти бели гранули.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Гранулите се предоставят в сашета.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;text-indent:-13.5pt"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка от 56 сашета (съдържа 4</span><span lang="EN-GB"> </span><span lang="BG">индивидуални карти тип „портфейл“, всяка с по 14 сашета).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Притежател на разрешението за употреба</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Vertex Pharmaceuticals (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="EN-GB">Ирландия</span><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Тел.: </span><span lang="EN-GB">+353 (0)1 761 7299</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Производител</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Almac Pharma Services (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Finnabair Industrial Estate</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dundalk</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Co. Louth</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">A91 P9KD</span></p><p class="MsoNormal"><span lang="EN-GB">Ирландия</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Almac</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Pharma</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Services</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Seagoe</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Industrial</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Estate</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Craigavon</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">County</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Armagh</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">BT</span><span lang="BG" style="color:black;background:lightgrey">63 5</span><span lang="EN-GB" style="color:black;background:lightgrey">UA</span></p><p class="MsoNormal"><span lang="BG" style="color:black;background:lightgrey">Обединено кралство</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Дата на последно преразглеждане на листовката "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><i><span lang="BG"> </span></i></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Други източници на информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Подробна информация за това лекарствo е предоставена на уебсайта на Европейската агенция по лекарствата</span><span lang="BG"> </span><span lang="EN-GB"><a href="http://www.emea.europa.eu"><span lang="BG">http://www.ema.europa.eu</span></a></span><span lang="BG" style="color:blue">.</span><span lang="BG"> Посочени </span><span lang="BG">са също линкове към други уебсайтове, където може да се намери информация за редки заболявания и лечения.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       Съдържание на опаковката и допълнителна информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">1.       </span></b><b><span lang="BG">Какво представлява Kalydeco и за какво се използва</span></b></p><p class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG">Kalydeco съдържа активната съставка ивакафтор. Ивакафтор действа на нивото на регулатора на трансмембранната проводимост </span><span lang="BG">при кистозна фиброза (CFTR), белтък, който образува канал на клетъчната повърхност, позволяващ движението на частици, като например хлорни йони, навътре и навън от клетката. Поради мутации на гена <i>CFTR</i> (вижте по-долу), движението на хлорните йони е ограничено при хора с кистозна фиброза (КФ). Ивакафтор помага на някои от белтъците CFTR с отклонения да се отварят по-често, за да се подобри движението на хлорните йони навътре и навън от клетката.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Гранулите Kalydeco са предназначени за лечение на бебета и </span><span lang="BG" style='font-family:"Times New Roman",serif'>деца на възраст 4 и повече месеца и с тегло от 5</span><span style='font-family:"Times New Roman",serif'> kg</span><span lang="BG" style='font-family:"Times New Roman",serif'> до под 25</span><span style='font-family:"Times New Roman",serif'> kg</span><span style='font-family:"Times New Roman",serif'> <span lang="BG">с кистозна фиброза (КФ), които имат </span></span><i><span style='font-family:"Times New Roman",serif'>R117H CFTR</span></i><span style='font-family:"Times New Roman",serif'> </span><span lang="BG" style='font-family:"Times New Roman",serif'>мутация или една от следните водещи до каналопатии мутации на <i>CFTR</i> гена: <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>или<i> S549R</i>.</span></p><p class="MsoNormal" style="text-autospace:none"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">2.       </span></b><b><span lang="BG">Какво трябва да знаете, преди Вашето дете да приеме Kalydeco</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Да не се приема Kalydeco</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ако Вашето дете е алергично към ивакафтор или към някоя от останалите съставки на това лекарство (изброени в точка 6).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Предупреждения и предпазни мерки </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете с лекаря на Вашето дете, ако детето Ви има или преди това е имало чернодробни проблеми</span><span lang="BG">. </span><span lang="BG">Може да се </span><span lang="BG">наложи</span><span lang="BG"> лекарят на Вашето дете да коригира дозата му.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">При някои хора, приемащи </span><span lang="BG">Kalydeco</span><span lang="BG">, се наблюдават повишени чернодробни ензими в кръвта. Веднага кажете на лекаря на Вашето дете, ако то има някои от тези симптоми, които могат да са признаци на чернодробни проблеми:</span></p><ul style="margin-top:0in" type="disc"> <li class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">болка или      дискомфорт      в горната      дясна част      на корема</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">пожълтяване      на кожата      или на      бялото на      очите</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">загуба      на апетит</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">гадене      или      повръщане</span></li> <li class="MsoNormal" style="text-autospace:none"><span lang="BG">тъмна      урина.</span></li> </ul><li class="MsoNormal" style="page-break-after:avoid;text-autospace:none"><span lang="BG">болка или      дискомфорт      в горната      дясна част      на корема</span></li><span lang="BG">болка или      дискомфорт      в горната      дясна част      на корема</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">пожълтяване      на кожата      или на      бялото на      очите</span></li><span lang="BG">пожълтяване      на кожата      или на      бялото на      очите</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">загуба      на апетит</span></li><span lang="BG">загуба      на апетит</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">гадене      или      повръщане</span></li><span lang="BG">гадене      или      повръщане</span><li class="MsoNormal" style="text-autospace:none"><span lang="BG">тъмна      урина.</span></li><span lang="BG">тъмна      урина.</span><p class="MsoNormal" style="margin-left:21.3pt"><span lang="BG">Преди и по време на лечението на Вашето дете, особено през първата година и по-специално ако кръвните изследвания показват чернодробни ензими в миналото, лекарят на Вашето дете ще направи някои кръвни изследвания, за да провери черния му дроб</span><span lang="RU">.</span></p><p class="MsoNormal" style="margin-left:21.3pt"><span lang="RU"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Говорете с лекаря на Вашето дете, ако Ви е известно, че то има или преди това е имало бъбречни проблеми. </span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">Kalydeco</span><span lang="BG"> не се препоръчва за пациенти, които са претърпели трансплантация на орган.</span></p><p class="MsoListParagraph" style="margin-left:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">При някои деца и юноши по време на лечението се наблюдава аномалия на очната леща (перде), без да се повлиява зрението. </span></p><p class="MsoNormal" style="margin-left:21.3pt"><span lang="BG">Лекарят на Вашето дете може да проведе очни прегледи преди и по време на лечението с </span><span lang="BG">ивакафтор</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Деца </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не давайте това лекарство на </span><span lang="BG">деца под 4‑месечна възраст, тъй като не е известно дали </span><span lang="BG">ивакафтор </span><span lang="BG">е безопасен и ефикасен при тези деца</span><span lang="BG">.</span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Други лекарства и Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Трябва да кажете на лекаря на Вашето дете или фармацевта</span><span lang="BG">, ако то използва, наскоро е използвало или е възможно да използва други лекарства. Някои лекарства могат да повлияят начина, по който действа </span><span lang="EN-GB">Kalydeco</span><span lang="BG">, или да повишат вероятността </span><span lang="BG">да получите</span><span lang="BG"> нежелани реакции. По-специално, информирайте лекаря на Вашето дете, ако то приема някое от изброените по-долу лекарства. Лекарят на Вашето дете може да реши да коригира дозата му или да реши, че са нужни допълнителни прегледи.</span><span lang="BG"> </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">противогъбични лекарства</span></b><span lang="BG"> (използвани за лечението на гъбични инфекции). Те включват </span><span lang="BG">флуконазол, итраконазол,</span><span lang="BG"> </span><span lang="BG">кетоконазол, позаконазол и вориконазол.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">антибиотици </span></b><span lang="BG">(използвани за лечението на бактериални инфекции). Те включват </span><span lang="BG">кларитромицин, еритромицин, рифабутин, рифампицин и телитромицин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства</span></b><span lang="BG"> <b>при епилепсия</b> (използвани за лечение на епилептични припадъци</span><span lang="BG"> </span><span lang="BG">или гърчове). Те включват</span><span lang="BG"> карбамазепин,</span><span lang="BG"> </span><span lang="BG">фенобарбитал и фенитоин.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">билкови </span></b><b><span lang="BG">лекарства.</span></b><span lang="BG"> Те включват жълт кантарион (<i>Hypericum perforatum</i>).</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">имуносупресори</span></b><span lang="BG"> (използвани след органна трансплантация). Те включват </span><span lang="BG">циклоспорин, </span><span lang="BG">еверолимус, сиролимус и </span><span lang="BG">такролимус</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">сърдечни гликозиди</span></b><span lang="BG"> (използвани за лечение на някои сърдечни заболявания). Те включват дигоксин</span><span lang="BG">.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">антикоагуланти</span></b><span lang="BG">(използвани за предотвратяване на кръвни съсиреци). Те включват варфарин. </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства за диабет.</span></b><span lang="BG"> Те включват глимепирид и глипизид.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">лекарства за понижаване на кръвното налягане. </span></b><span lang="BG">Те включват верапамил.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Kalydeco с храна и напитки</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="labeltext"><span lang="BG" style='font-family:"Times New Roman",serif'>Избягвайте да давате на Вашето дете храни или напитки, съдържащи грейпфрут, по време на лечението с Kalydeco, тъй като те могат да увеличат нежеланите реакции на Kalydeco, като повишат количеството ивакафтор в организма му.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Шофиране и работа с машини</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Kalydeco може да причини замаяност на Вашето дете. Ако детето Ви почувства замаяност, се препоръчва да не кара колело или да прави каквото и да е, което изисква цялото му внимание.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><b><span lang="BG">Важна информация за съдържанието на Kalydeco</span></b></p><p class="MsoNormalIndent" style="margin:0in;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormalIndent" style="margin:0in"><b><span lang="BG">Kalydeco съдържа лактоза. </span></b><span lang="BG">Ако лекарят на Вашето дете Ви е казал, че то има непоносимост към някои захари, свържете се с него, преди детето Ви да вземе това лекарство.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in"><b><span lang="BG">Kalydeco </span></b><b><span lang="BG">съдържа по-малко от 1</span></b><b><span lang="EN-GB"> </span></b><b><span lang="BG">mmol</span></b><span lang="BG"> <b>натрий</b> (23</span><span lang="EN-GB"> </span><span lang="BG">mg) на доза, т.е. може да се каже, че практически не съдържа натрий.</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">3.       </span></b><b><span lang="BG">Как се приема Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Винаги давайте това лекарство на Вашето дете точно както Ви е казал неговият лекар. Ако не сте сигурни в нещо, попитайте лекаря на Вашето дете. </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Лекарят на Вашето дете ще определи правилната доза за детето. Вашето дете трябва да продължи да приема всички други лекарства, освен ако лекарят на Вашето дете не му каже да спре някои от тях.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Препоръки за дозиране на Kalydeco са дадени в Таблица 1.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><i><span lang="BG"> </span></i></b></p><p class="MsoNormal" style="margin-bottom:6.0pt;page-break-after:avoid"><b><span lang="BG">Таблица 1: Препоръки за дозиране за деца на възраст 4 месеца</span></b><b><span lang="BG"> </span></b><b><span lang="BG">и по-големи</span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:99.0%;border-collapse:collapse;border:none" width="99%"> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Възраст</span></b></p> </td> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Тегло</span></b></p> </td> <td style="width:36.18%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Доза</span></b></p> </td> <td style="width:20.46%;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Обща   дневна доза</span></b></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   4 месеца до   под 6 месеца</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">5</span><span lang="EN-GB"> kg</span><span lang="BG"> или   повече</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от </span><span lang="EN-GB">25</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули,   приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">50</span><span lang="BG"> </span><span lang="EN-GB">mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td rowspan="4" style="width:21.68%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">6</span><span lang="BG"> и повече   месеца</span></p> </td> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   5</span><span lang="EN-GB"> kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под 7</span><span lang="EN-GB"> kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от </span><span lang="EN-GB">25</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули   Kalydeco, приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини </span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">50 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">7 kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под </span><span lang="EN-GB">14 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от </span><span lang="EN-GB">50</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули   Kalydeco, приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини </span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">100 mg</span></p> </td> </tr> <tr style="height:10.85pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="21%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">от   </span><span lang="EN-GB">14 kg </span><span lang="BG">до</span><span lang="BG"> </span><span lang="BG">под </span><span lang="EN-GB">25 kg</span></p> </td> <td style="width:36.18%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="36%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Едно   саше от 7</span><span lang="EN-GB">5</span><span lang="BG"> </span><span lang="EN-GB">mg </span><span lang="BG">гранули   Kalydeco, приемани   пeрорално на   всеки 12 часа   с храна,   съдържаща   мазнини</span></p> </td> <td style="width:20.46%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:10.85pt" valign="top" width="20%"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">150 mg</span></p> </td> </tr> <tr style="height:15.7pt"> <td style="width:21.68%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="21%"> <p class="MsoNormal"><span lang="BG">2</span><span lang="EN-GB">5 kg</span><span lang="BG"> и повече</span></p> </td> <td colspan="2" style="width:56.64%;border-top:none;   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt;height:15.7pt" valign="top" width="56%"> <p class="MsoNormal"><span lang="BG">Вижте листовката   на Kalydeco таблетки</span></p> </td> </tr> </table><p class="MsoNormal" style="text-autospace:none"><span class="s10"><span lang="BG"> </span></span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG">Ако Вашето дете има чернодробни проблеми</span></b><span lang="BG">, може да се наложи лекарят на Вашето дете да намали дозата Kalydeco, тъй като черният дроб на детето Ви няма да изчиства лекарството толкова бързо, колкото при децата с нормална чернодробна функция. </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">Умерени чернодробни проблеми при деца на възраст 6 и повече месеца:</span></b><span lang="BG"> дозата може да се понижи до половината от указаната в горната таблица доза, тоест едно саше веднъж дневно.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">Тежки чернодробни проблеми при деца на възраст 6 и повече месеца:</span></b><span lang="BG"> препоръчва се да не се използва, но лекарят на Вашето дете ще реши дали е подходящо за детето да употребява това лекарство, в който случай дозата (както е указана в горната таблица) трябва да се понижи до едно саше през ден.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><b><span lang="BG">Чернодробни проблеми при деца на възраст между 4 и 6 месеца:</span></b><span lang="BG"> препоръчва се да не се използва, но лекарят на Вашето дете ще реши дали е подходящо за детето да употребява това лекарство и в каква доза.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Kalydeco е за перорално приложение.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Всяко саше е само за еднократна употреба.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Как да давате Kalydeco на Вашето дете:</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol;color:black">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style="color:black">Хванете сашето с гранули, така че пунктираната линия за отрязване да е отгоре.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol;color:black">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style="color:black">Леко разклатете сашето, за да се събере съдържанието му.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol;color:black">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG" style="color:black">Откъснете или отрежете сашето по пунктираната линия. </span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Смесете цялото съдържание на едно саше с </span><span lang="BG" style="color:black">5 ml</span><span lang="BG"> подходяща за възрастта мека храна или течност. Храната или течността трябва да са със стайна или по-ниска температура. Някои примери за подходящи за възрастта меки храни или течности са плодово или зеленчуково пюре, кисело мляко, ябълково пюре, вода, мляко, </span><span lang="RU">кърма, мляко на прах за кърмачета </span><span lang="BG">или сок.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">След като смесите продукта, дайте го веднага на Вашето дете. Ако това не е възможно, дайте го в рамките на следващия един час след смесването. Внимавайте цялата смес да бъде приета веднага.</span></p><p class="MsoNormal" style="margin-left:21.3pt;text-indent:-21.3pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Непосредствено преди или непосредствено след приложението трябва да се приеме основно хранене или закуска, богати на мазнини (някои примери са дадени по-долу). </span></p><p class="MsoNormal"><span lang="BG" style="color:black"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Основни хранения и закуски, които съдържат мазнини, са ястията, приготвени с масло или различни видове олио, или съдържащите яйца. Други храни, съдържащи мазнини, са:</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">сирене и кашкавал, пълномаслено мляко, млечни продукти от пълномаслено мляко, кисело мляко, </span><span lang="RU">кърма, мляко на прах за кърмачета</span><span lang="EN-GB">,</span><span lang="EN-GB"> </span><span lang="BG">шоколад</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">месо</span>, <span lang="BG">мазна риба</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="RU" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">авокадо</span><span lang="RU">, </span><span lang="BG">хумус</span><span lang="RU">, </span><span lang="BG">продукти на соева основа </span><span lang="RU">(</span><span lang="BG">тофу</span><span lang="RU">)</span></p><p class="MsoNormal" style="margin-left:14.2pt;text-indent:-14.2pt"><span lang="RU" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">ядки</span><span lang="RU">, </span><span lang="BG">съдържащи мазнини, хранителни блокчета или напитки.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Ако Вашето дете е приело повече от необходимата доза Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Вашето дете може да получи нежелани реакции, включително упоменатите в точка</span><span lang="EN-GB"> </span><span lang="BG">4 по-долу. Ако това е така, потърсете лекаря на Вашето дете или фармацевта за съвет. Ако е възможно, носете лекарството на Вашето дете и тази листовка със себе си.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Ако Вашето дете е пропуснало да приеме Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal"><span lang="BG">Дайте пропуснатата доза, ако са изминали по-малко от 6 часа от момента, в който Вашето дете я е пропуснало. В противен случай изчакайте до следващата доза на Вашето дете по схемата, както нормално бихте направили. Не давайте на Вашето дете двойна доза, за да компенсирате пропусната доза.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Ако сте спрели да давате Kalydeco на Вашето дете</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Давайте </span><span lang="EN-GB">Kalydeco</span><span lang="BG"> на Вашето дете толкова дълго, колкото е препоръчал неговият лекар. Не спирайте, освен ако лекарят на Вашето дете не Ви посъветва за това. Ако имате някакви допълнителни въпроси, свързани с употребата на това лекарство, попитайте лекаря на Вашето дете или фармацевта.</span></p><p class="MsoNormal" style="margin-right:-.1pt"> </p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">4.       </span></b><b><span lang="BG">Възможни нежелани реакции</span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Както всички лекарства, това лекарство може да предизвика нежелани реакции, въпреки че не всеки ги получава. </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Сериозни нежелани реакции</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Болка в стомаха (корема) и повишени чернодробни ензими в кръвта. </span></p><p class="MsoNormal"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-1.45pt"><b><span lang="BG">Възможни признаци на чернодробни проблеми</span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Повишението на чернодробните ензими в кръвта е често срещано при пациенти с КФ. Това може да е признак на чернодробни проблеми:</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка или дискомфорт в горната дясна област на стомаха (корема)</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">пожълтяване на кожата или бялата част на очите</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">загуба на апетит</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">гадене или повръщане</span></p><p class="MsoListParagraph" style="margin-right:-1.45pt;text-indent:-.25in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">тъмна урина.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-1.45pt"><span lang="BG">Говорете незабавно с лекаря на Вашето дете, ако получите някои от тези нежелани реакции.</span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Много чести</span></b><span lang="BG"> нежелани реакции (могат да засегнат повече от 1 на 10 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">инфекция на горните дихателни пътища (настинка), включително възпалено гърло и запушен нос</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">главоболие </span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">замаяност</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">диария</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">обрив</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">промени във вида на бактериите в храчките.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Чести</span></b><span lang="BG"> нежелани реакции (могат да засегнат до 1 на 10 души)</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">хрема</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">болка в ухото, ушен дискомфорт</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">звънене в ушите</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">зачервяване на вътрешността на ухото </span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарушение на вътрешното ухо (замайване или световъртеж)</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">запушване на синусите</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in;page-break-after: avoid"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">зачервяване на гърлото</span></p><p class="MsoNormal" style="margin-left:.5in;text-indent:-.5in"><span lang="BG" style="font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">бучка в гърдата.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><b><span lang="BG">Нечести</span></b><span lang="BG"> </span><span lang="BG">нежелани реакции (могат да засегнат до 1 на 100 души)</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">запушване на ухото</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">възпаление на гърдата</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">нарастване на гърдата при мъже</span></p><p class="MsoNormal" style="margin-left:.25in;text-indent:-.25in"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">изменения или болка в гръдното зърно.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:avoid"><b><span lang="BG">Допълнителни нежелани реакции при деца и юноши</span></b></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;margin-bottom:.0001pt;text-indent:0in;page-break-after:avoid"><span lang="RU"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:0in;margin-bottom:.0001pt;text-indent:0in"><span lang="BG">Нежеланите реакции при деца <span style="display:none">и юноши</span> са подобни на тези, наблюдавани при възрастните. Повишени чернодробни ензими в кръвта обаче се наблюдават по-често при малки деца</span><span lang="RU">.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="RU"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Съобщаване на нежелани реакции</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Ако Вашето дете получи някакви нежелани лекарствени реакции, уведомете лекаря или фармацевта на Вашето дете. Това включва всички възможни,<span style="color:red"> </span>неописани в тази листовка нежелани реакции. Можете също да съобщите нежелани реакции директно чрез <span style="background:lightgrey">националната система за съобщаване, посочена в </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span lang="BG" style="background:lightgrey">Приложение V</span></a></span><span lang="BG">. Като съобщавате нежелани реакции, можете да дадете своя принос за получаване на повече информация относно безопасността на това лекарство.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after: avoid"><b><span lang="BG">5.       </span></b><b><span lang="BG">Как да съхранявате</span></b><b><span lang="BG"> Kalydeco</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Да се </span><span lang="BG">съхранява на място, недостъпно за деца.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не използвайте това лекарство след срока на годност, отбелязан върху опаковката след „Годен до:“ и „</span><span lang="EN-GB">EXP</span><span lang="BG">“.</span><span lang="BG"> Срокът на годност отговаря на последния ден от посочения месец.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Това лекарство не изисква специални условия на съхранение.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Доказано е, че след като се смеси, сместа е стабилна в продължение на един час.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Не изхвърляйте лекарствата</span><span lang="BG"> в канализацията или в контейнера за домашни отпадъци. Попитайте Вашия фармацевт как да изхвърляте лекарствата, които вече не използвате. Тези мерки ще спомогнат за опазване на околната среда.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Какво съдържа Kalydeco"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG">Kalydeco 25 mg гранули в саше:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><span lang="BG">Активно вещество: ивакафтор. Всяко саше съдържа 25 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG">Kalydeco 50 mg гранули в саше:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG">Активно вещество: ивакафтор. Всяко саше съдържа 50 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG">Kalydeco 75 mg гранули в саше:</span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;page-break-after:avoid"><u><span lang="BG"><span style="text-decoration:none"> </span></span></u></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><span lang="BG">Активно вещество: ивакафтор. Всяко саше съдържа 75 mg ивакафтор.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt"><i><span lang="BG"> </span></i></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:.25in;margin-bottom:.0001pt"><span lang="BG">Други съставки: </span><span lang="BG">силициев диоксид, колоиден безводен, кроскармелоза натрий, хипромелозен ацетат сукцинат, лактоза монохидрат, магнезиев стеарат, м</span><span lang="BG">анитол, захароза и натриев лаурилсулфат</span><span lang="BG"> </span><span lang="EN-GB">(E487).</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG">Вижте края на точка</span><span lang="EN-GB"> </span><span lang="BG">2 - „</span><span lang="BG">Важна информация</span><span lang="BG"> за съдържанието на Kalydeco“.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><b><span lang="BG"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Как изглежда Kalydeco и какво съдържа опаковката"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal"><span lang="BG">Kalydeco 25</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">гранули в саше са бели до почти бели гранули.</span></p><p class="MsoNormal"><span lang="BG">Kalydeco 50</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">гранули в саше са бели до почти бели гранули.</span></p><p class="MsoNormal"><span lang="BG">Kalydeco 75</span><span lang="EN-GB"> mg</span><span lang="EN-GB"> </span><span lang="BG">гранули в саше са бели до почти бели гранули.</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="BG">Гранулите се предоставят в сашета.</span></p><p class="MsoNormal" style="margin-top:0in;margin-right:-.1pt;margin-bottom:0in; margin-left:13.5pt;margin-bottom:.0001pt;text-indent:-13.5pt"><span lang="BG" style="font-size:8.0pt;font-family:Symbol">·<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="BG">Опаковка от 56 сашета (съдържа 4</span><span lang="EN-GB"> </span><span lang="BG">индивидуални карти тип „портфейл“, всяка с по 14 сашета).</span></p><p class="MsoNormal"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Притежател на разрешението за употреба</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Vertex Pharmaceuticals (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">28-32 Pembroke Street Upper</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dublin 2, D02 EK84</span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="EN-GB">Ирландия</span><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Тел.: </span><span lang="EN-GB">+353 (0)1 761 7299</span></p><p class="MsoNormalIndent" style="margin:0in"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG">Производител</span></b></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><b><span lang="BG"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Almac Pharma Services (Ireland) Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Finnabair Industrial Estate</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Dundalk</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Co. Louth</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">A91 P9KD</span></p><p class="MsoNormal"><span lang="EN-GB">Ирландия</span></p><p class="MsoNormal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Almac</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Pharma</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Services</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Limited</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Seagoe</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Industrial</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Estate</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">Craigavon</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">County</span><span lang="EN-GB" style="color:black;background:lightgrey"> </span><span lang="EN-GB" style="color:black;background:lightgrey">Armagh</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black;background:lightgrey">BT</span><span lang="BG" style="color:black;background:lightgrey">63 5</span><span lang="EN-GB" style="color:black;background:lightgrey">UA</span></p><p class="MsoNormal"><span lang="BG" style="color:black;background:lightgrey">Обединено кралство</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Дата на последно преразглеждане на листовката "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"><i><span lang="BG"> </span></i></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Други източници на информация"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="BG"> </span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="BG">Подробна информация за това лекарствo е предоставена на уебсайта на Европейската агенция по лекарствата</span><span lang="BG"> </span><span lang="EN-GB"><a href="http://www.emea.europa.eu"><span lang="BG">http://www.ema.europa.eu</span></a></span><span lang="BG" style="color:blue">.</span><span lang="BG"> Посочени </span><span lang="BG">са също линкове към други уебсайтове, където може да се намери информация за редки заболявания и лечения.</span></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>